|
|
Exchange: |
N/A |
Security
Type: |
N/A |
Shares
Out: |
43,711,000 |
Market
Cap: |
N/A |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$ - $ |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Kinnate is a clinical stage biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for genomically defined cancers. Co.'s focus is on three patient populations: those with cancers that harbor known oncogenic drivers with no available targeted therapies; those with genomically well-characterized tumors that have resistance to available treatments; and those whose tumors have acquired resistance over the course of therapy to available treatments. Co.'s product candidates are KIN002787, which is for the treatment of patients with lung cancer, melanoma and other solid tumors; and KIN-3248, which is targeting cancer-associated alterations in FGFR2.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
9,292,200 |
Total Buy Value |
$0 |
$0 |
$0 |
$25,488,272 |
Total People Bought |
0 |
0 |
0 |
4 |
Total Buy Transactions |
0 |
0 |
0 |
12 |
Total Shares Sold |
0 |
0 |
0 |
0 |
Total Sell Value |
$0 |
$0 |
$0 |
$0 |
Total People Sold |
0 |
0 |
0 |
0 |
Total Sell Transactions |
0 |
0 |
0 |
0 |
End Date |
2024-06-27 |
2024-03-26 |
2023-09-26 |
2022-09-26 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Orbimed Capital Llc |
Director |
|
2023-05-04 |
4 |
B |
$2.75 |
$1,319,750 |
I/I |
479,909 |
877,827 |
2.25 |
- |
|
Orbimed Capital Llc |
Director |
|
2023-05-02 |
4 |
B |
$2.67 |
$903,160 |
I/I |
338,262 |
794,368 |
2.25 |
- |
|
Gordon Carl L |
Director |
|
2023-05-02 |
4 |
B |
$2.67 |
$903,160 |
I/I |
338,262 |
794,368 |
2.25 |
- |
|
Orbimed Capital Llc |
Director |
|
2023-05-01 |
4 |
B |
$2.62 |
$1,876,331 |
I/I |
716,157 |
735,542 |
2.25 |
- |
|
Gordon Carl L |
Director |
|
2023-05-01 |
4 |
B |
$2.62 |
$1,876,331 |
I/I |
716,157 |
735,542 |
2.25 |
- |
|
Orbimed Capital Llc |
Director |
|
2023-04-28 |
4 |
B |
$2.55 |
$894,410 |
I/I |
350,749 |
610,997 |
2.25 |
- |
|
Gordon Carl L |
Director |
|
2023-04-28 |
4 |
B |
$2.55 |
$894,410 |
I/I |
350,749 |
610,997 |
2.25 |
- |
|
Williams Richard Thomas |
Chief Medical Officer |
|
2023-03-01 |
4 |
D |
$5.21 |
$3,324 |
D/D |
(638) |
67,295 |
|
- |
|
Meltz Mark A |
COO General Counsel Secretary |
|
2023-03-01 |
4 |
D |
$5.21 |
$3,324 |
D/D |
(638) |
27,286 |
|
- |
|
Krishnamohan Neha |
Chief Financial Officer |
|
2023-03-01 |
4 |
D |
$5.21 |
$8,966 |
D/D |
(1,721) |
67,378 |
|
- |
|
Orbimed Advisors Iv Ltd |
Director |
|
2023-02-17 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
1,100,000 |
|
- |
|
Orbimed Capital Llc |
Director |
|
2023-02-17 |
4 |
A |
$0.00 |
$0 |
I/I |
1,100,000 |
550,000 |
|
- |
|
Tananbaum James B. |
Director |
|
2023-02-17 |
4 |
A |
$0.00 |
$0 |
I/I |
1,100,000 |
1,975,001 |
|
- |
|
Gordon Carl L |
Director |
|
2023-02-17 |
4 |
A |
$0.00 |
$0 |
I/I |
1,100,000 |
550,000 |
|
- |
|
Foresite Capital Opportunity Management V, Llc |
10% Owner |
|
2023-02-17 |
4 |
A |
$0.00 |
$0 |
I/I |
1,100,000 |
1,975,001 |
|
- |
|
Meltz Mark A |
COO General Counsel Secretary |
|
2022-12-01 |
4 |
D |
$7.75 |
$4,193 |
D/D |
(541) |
27,924 |
|
- |
|
Krishnamohan Neha |
Chief Financial Officer |
|
2022-12-01 |
4 |
D |
$7.75 |
$11,307 |
D/D |
(1,459) |
69,099 |
|
- |
|
Williams Richard Thomas |
Chief Medical Officer |
|
2022-12-01 |
4 |
D |
$7.75 |
$4,193 |
D/D |
(541) |
67,933 |
|
- |
|
Krishnamohan Neha |
Chief Financial Officer |
|
2022-09-01 |
4 |
A |
$0.00 |
$0 |
D/D |
67,500 |
69,015 |
|
- |
|
Meltz Mark A |
COO General Counsel Secretary |
|
2022-09-01 |
4 |
A |
$0.00 |
$0 |
D/D |
25,000 |
28,465 |
|
- |
|
Williams Richard Thomas |
Chief Medical Officer |
|
2022-09-01 |
4 |
A |
$0.00 |
$0 |
D/D |
25,000 |
68,474 |
|
- |
|
Williams Richard Thomas |
Chief Medical Officer |
|
2022-03-14 |
4 |
B |
$8.37 |
$209,250 |
D/D |
25,000 |
42,333 |
2.74 |
- |
|
Williams Richard Thomas |
Chief Medical Officer |
|
2022-03-11 |
4 |
B |
$8.64 |
$129,600 |
D/D |
15,000 |
17,333 |
2.74 |
- |
|
Gordon Carl L |
Director |
|
2022-02-15 |
4 |
B |
$9.96 |
$89,640 |
I/I |
9,000 |
3,509,030 |
2.1 |
- |
|
Orbimed Capital Llc |
Director |
|
2022-02-15 |
4 |
B |
$9.96 |
$89,640 |
I/I |
9,000 |
3,509,030 |
2.1 |
- |
|
62 Records found
|
|
Page 2 of 3 |
|
|